Targeting KCC2 and NKCC1 for spinal motor dysfunction: pharmacology, therapeutic opportunities, and translational...

Spinal motor dysfunction after injury or prolonged disuse remains a major clinical challenge, in part because disruption of chloride homeostasis can weaken inhibitory control in spinal motoneurons. The cation-chloride cotransporters KCC2 and NKCC1 are central molecular regulators of intracellular chloride concentration ([Cl^-]ᵢ), and their relative activities strongly influence efficacy of GABAergic and glycinergic inhibition. Following injury or reduced activity, changes in neuronal signaling, inflammation, and mechanical unloading can impair KCC2 function and alter NKCC1 activity, thereby shifting Cl^- gradients and reducing the effectiveness of inhibitory neurotransmission. These changes have been implicated in motoneuron hyperexcitability, spasticity, and abnormal reflex function. Here, we review the molecular mechanisms that regulate KCC2 and NKCC1 in spinal motoneurons under physiological and pathological conditions. Particular attention is given to activity-dependent pathways, including BDNF-TrkB, WNK-OSR1/SPAK, and HDAC-dependent regulation, and to their effects on transporter abundance, phosphorylation, and function. We also examine the therapeutic prospects of restoring Cl^- homeostasis, with emphasis on KCC2-enchancing compounds such as CLP290, NKCC1 inhibitors such as bumetanide, and approaches that combine pharmacological intervention with activity-based rehabilitation. Rather than considering these strategies in isolation, we discuss how their efficacy may depend on the underlying pathology, disease stage, and state of neuronal activity. We conclude by identifying important gaps in our understanding of Cl^- regulation in spinal motor disorders and by considering the experimental and translational steps needed to determine whether modulation of KCC2 and NKCC1 can provide meaningful therapeutic benefit.